Neoadjuvant Tebentafusp for Uveal Melanoma

This study tests tebentafusp — a targeted immunotherapy drug — given before surgery (as neoadjuvant treatment) for uveal melanoma, a rare type of eye cancer (melanoma of the eye). The drug specifically targets a protein called gp100, which is found on uveal melanoma cells, and requires a specific immune gene (HLA-A*02:01) to work. **You may be eligible if...** - You are 18 or older with a primary uveal melanoma (eye melanoma) - Your tumor is large (T3 or T4 category) and cannot be surgically removed without removing the entire eye - You have not yet received any treatment for this cancer - You carry the HLA-A*02:01 immune marker (a genetic test is required) - You are willing to have tumor biopsies **You may NOT be eligible if...** - You do not carry the HLA-A*02:01 genetic marker - You have already received treatment for uveal melanoma - Your tumor could be removed with surgery that preserves the eye - Your expected survival is less than 12 weeks Talk to your doctor to see if this trial is right for you.